The Valley Desk

Clinical trial reportClinical pharmacology in drug developmentPublished

Exposure-Response Relationship of Dostarlimab in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis 2 of Part 1 of the RUBY Trial

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Fox Chase Cancer Center, GSK, with Temple Health linked by the institution reference. Affiliation source

Publication record

Type
Clinical trial report
Venue
Clinical pharmacology in drug development
Published
Subject terms
Humans; Endometrial Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Carboplatin; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Models, Biological; Aged; Middle Aged; Female; Antibodies, Monoclonal, Humanized
PubMed ID
42555284
PubMed Central ID
PMC13440458
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal